These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 27766216)

  • 1. Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.
    Soni S; Ruhela RK; Medhi B
    Adv Pharm Bull; 2016 Sep; 6(3):319-335. PubMed ID: 27766216
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology-based drug delivery for central nervous system disorders.
    Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
    Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobiotechnology-based drug delivery to the central nervous system.
    Jain KK
    Neurodegener Dis; 2007; 4(4):287-91. PubMed ID: 17627131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
    Baby N; Patnala R; Ling EA; Dheen ST
    Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in nanomedicines for diagnosis of central nervous system disorders.
    Zhang X; Zhou J; Gu Z; Zhang H; Gong Q; Luo K
    Biomaterials; 2021 Feb; 269():120492. PubMed ID: 33153757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine-based immunotherapy for central nervous system disorders.
    Hanif S; Muhammad P; Chesworth R; Rehman FU; Qian RJ; Zheng M; Shi BY
    Acta Pharmacol Sin; 2020 Jul; 41(7):936-953. PubMed ID: 32467570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
    Al-Ahmady ZS
    Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
    Muldoon LL; Tratnyek PG; Jacobs PM; Doolittle ND; Christoforidis GA; Frank JA; Lindau M; Lockman PR; Manninger SP; Qiang Y; Spence AM; Stupp SI; Zhang M; Neuwelt EA
    AJNR Am J Neuroradiol; 2006 Mar; 27(3):715-21. PubMed ID: 16552023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders.
    Hassanzadeh P; Atyabi F; Dinarvand R
    Life Sci; 2017 Aug; 182():93-103. PubMed ID: 28583367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives.
    Ross AM; Mc Nulty D; O'Dwyer C; Grabrucker AM; Cronin P; Mulvihill JJE
    J Control Release; 2019 Feb; 296():202-224. PubMed ID: 30664977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.
    Rhaman MM; Islam MR; Akash S; Mim M; Noor Alam M; Nepovimova E; Valis M; Kuca K; Sharma R
    Front Cell Dev Biol; 2022; 10():989471. PubMed ID: 36120565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Getting into the Brain: Are We in Yet or Just Knocking at the Door?
    Nagpal K; Singh D; Bhatia A; Kumar P
    Crit Rev Ther Drug Carrier Syst; 2022; 39(3):1-44. PubMed ID: 35381134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Nanomedicine to the CNS Diseases.
    Carradori D; Gaudin A; Brambilla D; Andrieux K
    Int Rev Neurobiol; 2016; 130():73-113. PubMed ID: 27678175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.